Sai Life Sciences Limited has informed the Exchange regarding a press release dated August 28, 2025, titled "Press Release regarding commencement of second phase of production block at unit IV Bidar Facility.".
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Smallcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sai Life Sciences has completed Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka. Phase II adds approximately 91 KL of reactor capacity, taking PB-11's combined capacity to around 200 KL — the single largest reactor block at the Bidar site. With this addition, the total installed reactor capacity at the Bidar facility now stands at roughly 700 KL, spread across 12 production blocks. The expansion strengthens the company's large-scale API and intermediate manufacturing capabilities for regulated markets like the US, EU, and Japan. Sai Life Sciences operates as a CRDMO serving over 300 global innovator pharma and biotech clients, and its Bidar facility is approved by USFDA, PMDA (Japan), and CDSCO.
The capacity expansion supports Sai Life Sciences' growth as a CRDMO and signals confidence in rising client demand, which could positively influence revenue potential. For shareholders, it represents a step-up in operational scale, though the actual financial impact will depend on how quickly the new capacity is utilised.